PrEP, Truvada, and Gilead
BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4800 (Published 08 September 2016) Cite this as: BMJ 2016;354:i4800
- Andrew Jack, journalist, Financial Times, London
- andrew.jack{at}ft.com
What is the current status of Truvada for preventing HIV?
Truvada is a fixed dose combination of tenofovir and emtricitabine produced by the US drug company Gilead. It has been licensed for the treatment of HIV-1 infection in adults for more than a decade.
Recent studies have shown it also effective in “treatment as prevention” or pre-exposure prophylaxis (PrEP) among people at high risk. The US Food and Drug Administration approved Truvada for PrEP in 2012.1 The World Health Organization recommended it in 2014.2 It is already reimbursed in France and included in several national strategies.3
PROUD, a clinical trial conducted in England and published in 2015, showed that it reduced HIV infection by 86%, with modest side effects.4 No other antiretrovirals have been studied in such detail for their potential use in PrEP. …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.